ClinicalTrials.gg
CompletedNCT04909450Updated May 13, 2026Results posted

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

A Phase 1/2 interventional study of CSB-001 Ophthalmic Solution 0.1% and Vehicle Control in Neurotrophic Keratitis, sponsored by Claris Biotherapeutics, Inc.. Completed at 48 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Claris Biotherapeutics, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Keratitis with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Keratitis · United States.

Enrollment
9th of 25
131 · median 60
Started
2021
the only one that year
Phase 1/2
3 of 34
1 open now
Registered
27th of 34
by date
Lead sponsor
1 of 34
Claris Biotherapeutics, Inc.

Among the 34 studies in Keratitis with a site in United States, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2021, is one of 3 in phase 1/2, and was the 27th registered.

Keratitis

108 studies on the registry are indexed under Keratitis; 19 are open to participants now.

Browse Keratitis studies →

Open to participants now

4 of the 34 studies in Keratitis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Keratitis studies recruiting now, 6 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Keratitis with a site in United States, or all of them as a file.
02

Study summary

This study will enroll subjects with stage 2 or 3 neurotrophic keratitis. Subjects will be randomized in a 1:1 ratio to the CSB-001 investigational treatment arm or vehicle control arm. All subjects will dose with the randomized treatment four times daily for 8 weeks (controlled treatment phase). During the controlled treatment phase, subjects will return to the clinic weekly from Day 0 to Week 8, and again at Week 10. Subjects randomized to the vehicle arm who are not healed will have the opportunity to participate in an open-label uncontrolled treatment phase.

03

Conditions studied

  • Neurotrophic Keratitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with stage 2 (PED) or stage 3 (corneal ulcer) neurotrophic keratitis (NK). Subjects with bilateral NK may enroll in the study but only one eye will be selected as the study eye (worse eye) and be treated with test article.
  • Subjects with no clinical evidence of improvement in the PED or corneal ulcer within the 2 weeks prior to study enrollment despite the use of conventional non-surgical treatments for neurotrophic keratitis (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops and medications that can decrease corneal sensitivity; therapeutic contact lenses [either silicone hydrogel or rigid gas permeable]) as determined by the investigator or referring physician's medical record.
  • Subjects with clinical evidence of decreased corneal sensitivity within the area of the PED or corneal ulcer and outside of the area of the defect in at least one corneal quadrant in the study eye in the opinion of the investigator assessed with a cotton wisp.
  • Pinhole distance visual acuity score ≤ 75 ETDRS letters measured with a LogMAR chart (≥ 0.2 LogMAR, ≤ 20/32 Snellen or worse Snellen or ≤ 0.625 decimal fraction) in the study eye.
  • Subjects must have the ability and willingness to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Any active ocular infection (bacterial, viral, fungal, or protozoal) or active ocular inflammation not related to NK in either eye in the opinion of the investigator. Infectious epithelial keratitis including herpetic keratitis (i.e., dendritic lesions or geographic ulcers) in either eye is excluded. Subjects on oral antibiotic at the time of screening are eligible but should continue the medication for the duration of the study.
  • Previous use of Oxervate in the study eye with last administration within the past 2 months.
  • Any other ocular disease, except glaucoma, that will require topical ocular treatment in the study eye over the course of the study.
  • Use of any other topical treatments other than the study medication provided by the Sponsor and allowed by the study protocol can be administered to the study eye over the course of the study. The following are exceptions: a) Allowance for use of preservative-free antibiotic eye drops if prescribed by the investigator and b) Allowance for use of a non-preserved IOP-lowering prostaglandin topical ocular drop administered once-daily (QD) in glaucomatous eyes over the course of the study.

Note: Other inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    CSB-001 Investigational Treatment Arm

    One drop CSB-001 four times daily for 8 weeks in the study eye

    Biological: CSB-001 Ophthalmic Solution 0.1%

  • Placebo comparator
    Vehicle Control Arm

    One drop matching vehicle four times daily for 8 weeks in the study eye

    Biological: Vehicle Control

Interventions

  • BiologicalCSB-001Studies of CSB-001CSB-001 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)

  • BiologicalVehicle Control

    Matching vehicle control without the drug substance

06

What researchers measure

Primary outcomes

  1. Efficacy as Assessed by Complete Corneal Healing

    Percentage of subjects achieving complete corneal healing in study eye as assessed by the Central Reading Center (CRC). Complete corneal healing was defined as absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 8 and the absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 10.

    Time frame: Week 8 through Week 10

  2. Safety as Assessed by Adverse Event Reporting

    Number of participants with ocular and systemic adverse events

    Time frame: Screening (Day 0) through Week 10

07

Results

Posted May 13, 2026

Participant flow

Participant flow — Overall Study
MilestoneCSB-001 Investigational Treatment ArmVehicle Control Arm
Started6962
Received csb-001 in uncontrolled investigational treatment arm025
Completed6256
Not completed76

Outcome measures

PrimaryEfficacy as Assessed by Complete Corneal Healing

Percentage of subjects achieving complete corneal healing in study eye as assessed by the Central Reading Center (CRC). Complete corneal healing was defined as absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 8 and the absence of corneal staining in the area of the defect/ulcer (i.e., 0 mm lesion) at Week 10.

Time frame:
Week 8 through Week 10
Reported as:
Count of participants · Participants
Efficacy as Assessed by Complete Corneal Healing
ParticipantsCSB-001 Investigational Treatment ArmVehicle Control Arm
Efficacy as Assessed by Complete Corneal Healing2116
PrimarySafety as Assessed by Adverse Event Reporting

Number of participants with ocular and systemic adverse events

Time frame:
Screening (Day 0) through Week 10
Reported as:
Count of participants · Participants
Safety as Assessed by Adverse Event Reporting
ParticipantsCSB-001 Investigational Treatment ArmVehicle Control Arm
Any ocular TEAEs (study eye)3235
Any systemic TEAEs1023

Adverse events

Collected over Controlled Treatment Phase: 10 weeks and Uncontrolled Treatment Phase: 10 weeks for a total of 20 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CSB-001 Investigational Treatment Arm2/69 (2.9%)8/69 (11.6%)18/69 (26.1%)
Vehicle Control Arm1/62 (1.6%)7/62 (11.3%)35/62 (56.5%)
CSB-001 Uncontrolled Investigational Treatment Arm0/25 (0%)1/25 (4%)5/25 (20%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventCSB-001 Investigational Treatment ArmVehicle Control ArmCSB-001 Uncontrolled Investigational Treatment Arm
AnemiaBlood and lymphatic system disorders0/690/621/25
HyponatremiaMetabolism and nutrition disorders0/690/621/25
Low hemoglobinInvestigations0/690/621/25
Neurotrophic keratopathyEye disorders2/691/620/25
CellulitisInfections and infestations0/691/620/25
OsteomyelitisInfections and infestations0/691/620/25
Pneumonia pseudomonalInfections and infestations0/691/620/25
FallInjury, poisoning and procedural complications1/691/620/25
Ankle fractureInjury, poisoning and procedural complications0/691/620/25
Haemoglobin decreasedInvestigations0/691/620/25
Most frequent other events
Most frequent other events
EventCSB-001 Investigational Treatment ArmVehicle Control ArmCSB-001 Uncontrolled Investigational Treatment Arm
Visual acuity reducedEye disorders3/694/623/25
Neurotrophic keratopathyEye disorders7/693/621/25
Eye irritationEye disorders2/695/620/25
Corneal oedemaEye disorders0/695/620/25
Instillation site painGeneral disorders1/695/621/25
COVID-19Infections and infestations1/695/620/25
Eye painEye disorders0/690/622/25
Ocular hyperaemiaEye disorders3/694/620/25
Conjunctival hyperaemiaEye disorders1/694/621/25

Baseline characteristics

Intent-to-Treat defined as all subjects who were randomized and had post-baseline efficacy data.

Age, Continuous
Age, Continuous(years)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
Mean64.3 ± 18.1368.1 ± 14.7266.1 ± 16.62
Age, Continuous
Age, Continuous(years)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
Median66.0 (25 to 94)72.0 (22 to 89)70.0 (22 to 94)
Age, Customized
Age, Customized(Participants)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
Age group, n (%) — < 60231336
Age group, n (%) — ≥ 60444993
Sex: Female, Male
Sex: Female, Male(Participants)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
Female383472
Male292857
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
Hispanic or Latino111324
Not Hispanic or Latino5649105
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
American Indian or Alaska Native112
Asian224
Native Hawaiian or Other Pacific Islander112
Black or African American325
White5655111
More than one race213
Unknown or Not Reported202
Current Neurotrophic Keratitis (NK) Stage
Current Neurotrophic Keratitis (NK) Stage(Participants)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
Stage 2494190
Stage 3182139
Time since Current NK stage Diagnosis
Time since Current NK stage Diagnosis(months)CSB-001 Investigational Treatment ArmVehicle Control ArmTotal
Median2.50 (0.0 to 209.0)2.45 (0.0 to 306.2)2.50 (0.0 to 306.2)
08

Study locations

48 sites
  • Eye Care North
    Cave Creek, Arizona 85331, United States
  • Loma Linda University Eye Institute
    Loma Linda, California 92354, United States
  • Nvision Clinical Research, LLC
    Los Angeles, California 90013, United States
  • Global Research Foundation
    Los Angeles, California 90041, United States
  • UCLA Stein Eye Institute
    Los Angeles, California 90095, United States
  • LoBue Laser and Eye Medical Center, Inc.
    Murrieta, California 92562, United States
  • California Eye Specialists Medical Group Inc.
    Pasadena, California 91107, United States
  • Martel Eye Medical Group
    Rancho Cordova, California 95670, United States
  • Gordon Schanzlin New Vision Institute
    San Diego, California 92122, United States
  • Atlantis Eyecare
    Torrance, California 90505, United States
  • University of Colorado - Dept. of Ophthalmology
    Aurora, Colorado 80045, United States
  • Vision Institute
    Colorado Springs, Colorado 80907, United States
  • Corneal Consultants of Colorado
    Littleton, Colorado 80120, United States
  • Advanced Research
    Boynton Beach, Florida 33437, United States
  • Bowden Eye and Associates
    Jacksonville, Florida 32256, United States
  • International Eye Associates, PA
    Ormond Beach, Florida 32174, United States
  • Bascom Palmer Eye Institute at Palm Beach Gardens
    Palm Beach, Florida 33418, United States
  • International Research Center
    Tampa, Florida 33603, United States
  • Eye Consultants of Atlanta
    Atlanta, Georgia 30339, United States
  • Midwest Cornea Associates, LLC
    Carmel, Indiana 46290, United States
  • Price Vision Group
    Indianapolis, Indiana 46260, United States
  • Cincinnati Eye Institute
    Edgewood, Kentucky 41017, United States
  • Kentucky Eye Institute
    Lexington, Kentucky 40517, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Cornea and Contact Lens Institute of Minnesota
    Edina, Minnesota 55436, United States
  • Minnesota Eye Consultants
    Minnetonka, Minnesota 55305, United States
  • Tauber Eye Center
    Kansas City, Missouri 64111, United States
  • Ophthalmology Associates
    St Louis, Missouri 63131, United States
  • Metropolitan Eye Research and Surgery Institute
    Palisades Park, New Jersey 07650, United States
  • SightMD
    Babylon, New York 11702, United States
  • Cornea Consultants of Albany
    Slingerlands, New York 12159, United States
  • Duke Eye Center
    Durham, North Carolina 27710, United States
  • Eye Consultants of North Dakota
    Fargo, North Dakota 58104, United States
  • The Ohio State University, Department of Ophthalmology and Visual Sciences
    Columbus, Ohio 43212, United States
  • Devers Eye Institute
    Portland, Oregon 97210, United States
  • Hazleton Eye Specialists
    Hazle Township, Pennsylvania 18202, United States
  • Scheie Eye Institute
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Eye Center
    Pittsburgh, Pennsylvania 15213, United States
  • Carolina Cataract & Laser Center
    Ladson, South Carolina 29456, United States
  • Vance Thompson Vision
    Sioux Falls, South Dakota 57108, United States
  • BLINK Research Center, LLC
    Memphis, Tennessee 38119, United States
  • University of Texas at Austin; The Mitchel and Shannon Wong Eye Institute
    Austin, Texas 78712, United States
  • Stuart A. Terry, MD PA
    San Antonio, Texas 78212, United States
  • Virginia Eye Consultants
    Norfolk, Virginia 23502, United States
  • Dr. Gregory Moloney
    Vancouver, British Columbia V5Z 1K1, Canada
  • Precision Cornea Centre
    Ottawa, Ontario K1G 5L1, Canada
  • Kensington Eye Institute
    Toronto, Ontario M5T 3A9, Canada
09

References and documents

Publications

  • Hamrah P, Yavuz Saricay L, Ozmen MC. Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy-Biologicals as a Novel Therapy for Neurotrophic Keratopathy. Cornea. 2022 Jun 1;41(6):673-679. doi: 10.1097/ICO.0000000000002974. Epub 2022 Feb 2. PubMed 35266655 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in May 2024, 32 months.

Results were first posted in May 2026, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2021
First posted
Jun 1, 2021
StartActual
Aug 24, 2021
Primary completionActual
May 7, 2024
CompletionActual
Jun 4, 2024
Results first posted
May 13, 2026
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04909450
Lead sponsor
Claris Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 1, 2021
Start date
Aug 24, 2021
Primary completion
May 7, 2024
Completion
Jun 4, 2024
Results posted
May 13, 2026
Last update
May 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CSB-001

Start the discussion